Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Saeed Rafii"'
Publikováno v:
Clinics and Practice, Vol 12, Iss 1, Pp 118-132 (2022)
The United Arab Emirates (UAE) is one of the fastest growing economies with consequent increase in non-communicable diseases including cancer. The number of reported cases and mortality have been increasing in the UAE over the years, despite screenin
Externí odkaz:
https://doaj.org/article/6c62d7a5f0a7422aad33bbbaec8b6282
Autor:
Humaid O. Al-Shamsi, Nadia Abdelwahed, Aydah Al-Awadhi, Mohamed Albashir, Amin M. Abyad, Saeed Rafii, Mehdi Afrit, Bilal Al Lababidi, Ibrahim Abu-Gheida, Yoginee Pundlik Sonawane, Neil A. Nijhawan, Urfan Ul Haq, Norbert Dreier, Thanda Lucy Ann Joshua, Faryal Iqbal, Tamer Yacoub, Faisal A. Nawaz, Dima Abdul Jabbar, Syed Hammad Tirmazy, Dalia M. El-shourbagy, Dina Hamza, Mohamed Omara, Sawsan Abdul Salam Al Madhi, Hassan Ghazal, Humaa Darr, Muharrem Oner, Zoi Vlamaki, Abdul Rahman El Kinge, Dorai Ramanathan, Mohammed Judah, Taghreed Almahmeed, Mudhasir Ahmad, Sai Babu Jonnada, Nahla Almansoori, Aly A. Razek, Annett Al-Hamadi, Nahed Balalaa, Faek Jamali, Ramanujam Anugonda Singarachari, Abdelrahman Labban, Kaltar Das, Ernest J.T. Luiten, Tamer Abdelgawad, Falah Al-Khatib, Sadir Alrawi, Hassan Jaafar
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
Externí odkaz:
https://doaj.org/article/1d4dfd88e83f471496fb96c307e1f39c
Autor:
Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura, James Spicer
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2019)
Abstract Background Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm A), with
Externí odkaz:
https://doaj.org/article/1caffbf612894f738efaee3a4d3d13dc
Autor:
Zev A. Wainberg, Lauren Averett Byers, Nicola J. Curtin, Miranda Patterson, Ashleigh Herriott, Joshua W. Henshaw, David C. Smith, John Heymach, Jasgit Sachdev, Stan Kaye, Saeed Rafii, John Glaspy, Rashmi Chugh, Lida Mina, Ramesh K. Ramanathan, Johann de Bono
Supplementary Figure S1. Talazoparib inhibition of PBMC PARP activity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e95db2be5b81e9a0f3ad86b8281bd1
https://doi.org/10.1158/2159-8290.22531110
https://doi.org/10.1158/2159-8290.22531110
Autor:
Zev A. Wainberg, Lauren Averett Byers, Nicola J. Curtin, Miranda Patterson, Ashleigh Herriott, Joshua W. Henshaw, David C. Smith, John Heymach, Jasgit Sachdev, Stan Kaye, Saeed Rafii, John Glaspy, Rashmi Chugh, Lida Mina, Ramesh K. Ramanathan, Johann de Bono
Supplementary Methods includes additional details on these topics: tumors eligible for dose escalation phase; tumors eligible for dose expansion phase; patients enrolled using a local laboratory; study design and participants; additional inclusion cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c35bb32f493e71bbc643b22bb0b3649
https://doi.org/10.1158/2159-8290.22531107.v1
https://doi.org/10.1158/2159-8290.22531107.v1
Autor:
Zev A. Wainberg, Lauren Averett Byers, Nicola J. Curtin, Miranda Patterson, Ashleigh Herriott, Joshua W. Henshaw, David C. Smith, John Heymach, Jasgit Sachdev, Stan Kaye, Saeed Rafii, John Glaspy, Rashmi Chugh, Lida Mina, Ramesh K. Ramanathan, Johann de Bono
Supplementary Table S1. Dose-response and exposure-response parameters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b99fccdd412f6f65d1dfdcba0f9d8d0
https://doi.org/10.1158/2159-8290.22531104
https://doi.org/10.1158/2159-8290.22531104
Autor:
Udai Banerji, Johann S. de Bono, Stanley B. Kaye, L. Rhoda Molife, Timothy A. Yap, Marta Capelan, Karim Rihawi, Begona Jimenez, Elena Geuna, Desamparados Roda, Saeed Rafii
Supplementary Figure 1. Occurence of infection during treatment with single agent PI3K-AKT-mTOR inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5442bc5f5e5b565285c420f7464091
https://doi.org/10.1158/1078-0432.22454603
https://doi.org/10.1158/1078-0432.22454603
Autor:
Udai Banerji, Johann S. de Bono, Stanley B. Kaye, L. Rhoda Molife, Timothy A. Yap, Marta Capelan, Karim Rihawi, Begona Jimenez, Elena Geuna, Desamparados Roda, Saeed Rafii
Purpose: Novel antitumor therapies against the PI3K–AKT–mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents are not known to be myelosu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::320b7e42897e6d957e72f275be463ae7
https://doi.org/10.1158/1078-0432.c.6522800
https://doi.org/10.1158/1078-0432.c.6522800
Publikováno v:
Cancers. 14:947
Cancer is considered by not only multiple genetic but also epigenetic amendments that drive malignant cell propagation and consult chemo-resistance. The ability to correct or ablate such mutations holds enormous promise for battling cancer. Recently,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fea0ade15fd7fa29ab30844076f0b27
https://doi.org/10.3390/cancers14040947
https://doi.org/10.3390/cancers14040947
Autor:
Javier Garcia-Corbacho, James Spicer, Jacques Bonneterre, Iain R. Macpherson, Pavlina Spiliopoulou, Mario Campone, Saeed Rafii, Richard D. Baird, J Posner, Matilde Saggese, Antoine Italiano, Yousuke Takeda, A Arimura, Nicola Cresti
Publikováno v:
MacPherson, I R, Spiliopoulou, P, Rafii, S, Saggese, M, Baird, R D, Garcia-Corbacho, J, Italiano, A, Bonneterre, J, Campone, M, Cresti, N, Posner, J, Takeda, Y, Arimura, A & Spicer, J 2019, ' A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer ', Breast Cancer Research, vol. 22, 1 . https://doi.org/10.1186/s13058-019-1178-0
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2019)
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2019)
Background Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm A), with trastuzum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c296f54e78364b1373c4fc5eded6ac
https://www.repository.cam.ac.uk/handle/1810/301079
https://www.repository.cam.ac.uk/handle/1810/301079